Brief: Biomea Fusion Announces First Patient Dosed With Covalent FLT3 Inhibitor BMF-500 In Relapsed Or Refractory Acute Leukemia In Phase I Clinical Trial
17/10/2023 14:34
Oct 17 (Reuters) - Biomea Fusion Inc BMEA.O :
* BIOMEA FUSION ANNOUNCES FIRST PATIENT DOSED WITH COVALENT
FLT3
INHIBITOR BMF-500 IN RELAPSED OR REFRACTORY ACUTE LEUKEMIA IN
PHASE I CLINICAL TRIAL (COVALENT-103)
* BIOMEA FUSION INC - PRECLINICAL STUDIES OF BMF-500 HAVE
SHOWN
PROMISING ACTIVITY AGAINST ALL KNOWN FLT3 ACTIVATING AND
RESISTANCE CONFERRING MUTATIONS
* BIOMEA FUSION INC - BEYOND SINGLE AGENT STUDIES OF BMF-500
PLANNING COMBINATION STUDIES WITH VARIOUS APPROVED THERAPIES AND
THERAPY CANDIDATES
Source text for Eikon: ID:nGNX7MPzvS
Further company coverage: BMEA.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Biomea Fusion
See all newsUS RESEARCH ROUNDUP-BlackRock, Microsoft, TransDigm Group
Brief: Biomea Fusion Announces Phase 1 Results For Bmf-650, Its Investigational Next-Generation Oral Small Molecule Glp-1 Receptor Agonist
Brief: Biomea Fusion To Announce Phase I Results For Bmf-650, Its Next-Generation Oral Small-Molecule Glp-1 Receptor Agonist
Brief: Biomea Fusion Announces Termination Of Proposed Public Offering Of Securities
Brief: Biomea Fusion Announces Completion Of Enrollment In Covalent-211 Phase Ii Trial Of Icovamenib In Insulin-Deficient Type 2 Diabetes